Bridgeway Capital Management’s NanoViricides NNVC Stock Holding History

Bridgeway Capital Management’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$49.7K	Hold	36,039	–	–	﹤0.01%	1203
2026 Q1	$32.9K	Hold	36,039	–	–	﹤0.01%	1199
2025 Q4	$40.7K	Hold	36,039	–	–	﹤0.01%	1191
2025 Q3	$51.5K	Sell	36,039 -8,000	-18%	-$12K	﹤0.01%	1167
2025 Q2	$61.7K	Hold	44,039	–	–	﹤0.01%	1123
2025 Q1	$51.5K	Hold	44,039	–	–	﹤0.01%	1118
2024 Q4	$63K	Hold	44,039	–	–	﹤0.01%	1148
2024 Q3	$66.1K	Sell	44,039 -15,000	-25%	-$27.8K	﹤0.01%	1198
2024 Q2	$102K	Hold	59,039	–	–	﹤0.01%	1163
2024 Q1	$68.5K	Hold	59,039	–	–	﹤0.01%	1245
2023 Q4	$60.2K	Hold	59,039	–	–	﹤0.01%	1298
2023 Q3	$79.1K	Sell	59,039 -35,000	-37%	-$49.5K	﹤0.01%	1258
2023 Q2	$108K	Hold	94,039	–	–	﹤0.01%	1246
2023 Q1	$110K	Hold	94,039	–	–	﹤0.01%	1221
2022 Q4	$104K	Hold	94,039	–	–	﹤0.01%	1209
2022 Q3	$163K	Hold	94,039	–	–	﹤0.01%	1175
2022 Q2	$177K	Hold	94,039	–	–	﹤0.01%	1119
2022 Q1	$197K	Hold	94,039	–	–	﹤0.01%	1174
2021 Q4	$350K	Hold	94,039	–	–	0.01%	1063
2021 Q3	$436K	Buy	94,039 +14,600	+18%	+$60.9K	0.01%	1074
2021 Q2	$369K	Sell	79,439 -22,000	-22%	-$88.8K	0.01%	1154
2021 Q1	$479K	Buy	101,439 +61,000	+151%	+$276K	0.01%	1095
2020 Q4	$116K	Hold	40,439	–	–	﹤0.01%	1256
2020 Q3	$155K	Hold	40,439	–	–	﹤0.01%	1212
2020 Q2	$302K	Buy	40,439 +22,000	+119%	+$153K	0.01%	1037
2020 Q1	$106K	Buy	+18,439	New	+$130K	﹤0.01%	1168
2017 Q4	–	Sell	-13,400	Closed	-$306K	–	1430
2017 Q3	$306K	Hold	13,400	–	–	﹤0.01%	1200
2017 Q2	$362K	Hold	13,400	–	–	﹤0.01%	1169
2017 Q1	$300K	Hold	13,400	–	–	﹤0.01%	1211
2016 Q4	$287K	Hold	13,400	–	–	﹤0.01%	1231
2016 Q3	$453K	Hold	13,400	–	–	0.01%	1130
2016 Q2	$429K	Hold	13,400	–	–	0.01%	1108
2016 Q1	$587K	Hold	13,400	–	–	0.01%	978
2015 Q4	$316K	Hold	13,400	–	–	0.01%	1193
2015 Q3	$319K	Buy	13,400 +4,392	+49%	+$116K	0.01%	1199
2015 Q2	$312K	Buy	9,008 +1,357	+18%	+$51.7K	0.01%	1240
2015 Q1	$344K	Sell	7,651 -2,224	-23%	-$119K	0.01%	1221
2014 Q4	$537K	Buy	9,875 +2,725	+38%	+$180K	0.01%	1021
2014 Q3	$429K	Hold	7,150	–	–	0.01%	1150
2014 Q2	$605K	Hold	7,150	–	–	0.02%	996
2014 Q1	$458K	Buy	+7,150	New	+$611K	0.01%	1114

Other funds holding NNVC

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MFS

Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Bridgeway Capital Management's NNVC Position: Q2 2026 in Review

Bridgeway Capital Management held its NanoViricides (NNVC) position steady in Q2 2026 at 36,039 shares worth $49.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1203.

Bridgeway Capital Management first reported a position in NNVC in Q1 2014 and has held it in 41 quarters since. The position peaked at $605K in Q2 2014. 48 funds tracked by Wall St. Rank hold NNVC as of Q2 2026.

Bridgeway Capital Management held 36,039 shares of NanoViricides worth $49.7K as of Q2 2026.
Bridgeway Capital Management left its NanoViricides share count unchanged in Q2 2026.
NanoViricides made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #1203 holding.
Bridgeway Capital Management first reported a position in NanoViricides in Q1 2014 and has held it in 41 quarters since.
Bridgeway Capital Management's NanoViricides position peaked at $605K in Q2 2014.
48 funds tracked by Wall St. Rank held NanoViricides as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.